François Chappuis

François Chappuis

Auto-generated profile, based on publicly available information

François Chappuis

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
FCFrançois Chappuis
François Chappuis
SSShyam Sundar
Shyam Sundar
AHAsrat Hailu
Asrat Hailu
HGHashim Ghalib
Hashim Ghalib
SRSuman Rijal
Suman Rijal
MBMarleen Boelaert
Marleen Boelaert

1 January 2005 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
FCFrançoIs Chappuis
FrançoIs Chappuis
LLLouis Loutan
Louis Loutan
PSPere Simarro
Pere Simarro
VLVeerle Lejon
Veerle Lejon
PBPhilippe BüsCher
Philippe BüsCher
SUMMARY: Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense or T. b. rhodesiense remains highly prevalent in several rural areas of sub-Saharan Africa and is lethal if left untreated. Therefore, accurate tools are absolutely required for field diagnosis. For T. b. gambiense HAT, highly sensitive tests are available for serological screening but the sensitivity of parasitological confirmatory tests remains insufficient and needs to be improved. Screening for T. b. rhodesiense infection still relies on clinical features in the absence of serological tests available for field use. Ongoing research is opening perspectives for a new generation of field diagnostics. Also essential for both forms of HAT is accurate determination of the disease stage because of the high toxicity of melarsoprol, the drug most widely used during the neurological stage of the illness. Recent studies have confirmed the high accuracy of raised immunoglobulin M levels in the cerebrospinal fluid for the staging of T. b. gambiense HAT, and a promising simple assay (LATEX/IgM) is being tested in the field. Apart from the urgent need for better tools for the field diagnosis of this neglected disease, improved access to diagnosis and treatment for the population at risk remains the greatest challenge for the coming years.

1 August 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
FCFrançois Chappuis
François Chappuis
SRSuman Rijal
Suman Rijal
ASAlonso Soto
Alonso Soto
JMJoris Menten
Joris Menten
MBMarleen Boelaert
Marleen Boelaert
Objective To compare the performance of the direct agglutination test and rK39 dipstick for the diagnosis of visceral leishmaniasis. Data sources Medline, citation tracking, January 1986 to December 2004. Selection criteria Original studies evaluating the direct agglutination test or the rK39 dipstick with clinical visceral leishmaniasis as target condition; adequate reference classification; and absolute numbers of true positive, true negative, false positive, and false negative observations available or derivable from the data presented. Results 30 studies evaluating the direct agglutination test and 13 studies evaluating the rK39 dipstick met the inclusion criteria. The combined sensitivity estimates of the direct agglutination test and the rK39 dipstick were 94.8% (95% confidence interval 92.7% to 96.4%) and 93.9% (87.7% to 97.1%), respectively. Sensitivity seemed higher and more homogenous in the studies carried out in South Asia. Specificity estimates were influenced by the type of controls. In phase III studies carried out on patients with clinically suspected disease, the estimated specificity of the direct agglutination test was 85.9% (72.3% to 93.4%) and of the rK39 dipstick was 90.6% (66.8% to 97.9%). Conclusion The diagnostic performance of the direct agglutination test and the rK39 dipstick for visceral leishmaniasis is good to excellent and seem comparable.

1 May 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
MNMayssam Nehme
Mayssam Nehme
OBOlivia Braillard
Olivia Braillard
GAGabriel Alcoba
Gabriel Alcoba
SPSigiriya Aebischer Perone
Sigiriya Aebischer Perone
DCDelphine Courvoisier
Delphine Courvoisier
IGIdris Guessous
Idris Guessous

1 August 2004 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
SSSanjib K. Sharma
Sanjib K. Sharma
FCFrançoIs Chappuis
FrançoIs Chappuis
NJNilhambar Jha
Nilhambar Jha
PBPatrick A. Bovier
Patrick A. Bovier
LLLouis Loutan
Louis Loutan
SKShekhar Koirala
Shekhar Koirala
Current available data on snake bites in Nepal are based solely on hospital statistics. This community-based study aimed at evaluating the impact of snake bites and determining the risk factors associated with a fatal outcome in southeastern Nepal. A total of 1,817 households, selected by a random proportionate sampling method, were visited by trained fieldworkers in five villages. Extensive data from snake bite victims during the 14 previous months were recorded and analyzed. One hundred forty-three snake bites including 75 bites with signs of envenoming were reported (annual incidence = 1,162/100,000 and 604/100,000, respectively), resulting in 20 deaths (annual mortality rate = 162/100,000). Characteristics of krait bites such as bites occurring inside the house, while resting, and between midnight and 6:00 am were all factors associated with an increased risk of death, as were an initial consultation with a traditional healer, a long delay before transport, and a lack of available transport. An initial transfer to a specialized treatment center and transport by motorcycle were strong protective factors. Among the 123 survivors, wounds required dressing and surgery in 30 (24%) and 10 (8%) victims, respectively, the mean working incapacity period was 15 days, and the mean out-of-pocket expense was 69 U.S. dollars. Snake bite is a major but neglected public health problem in southeastern Nepal. Public health interventions should focus on improving victims’ rapid access to anti-snake venom serum by promoting immediate and fast transport to adequate treatment centers, particularly for bites occurring at night.

20 November 2012 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Open access
MBManica Balasegaram
Manica Balasegaram
KRKoert Ritmeijer
Koert Ritmeijer
MLMaria Angeles Lima
Maria Angeles Lima
SBSakib Burza
Sakib Burza
GGGemma Ortiz Genovese
Gemma Ortiz Genovese
FCFrançois Chappuis
François Chappuis
Introduction: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients' access to this life-saving drug remain. Areas covered: This article provides a review of clinical studies on LAMB for VL and other forms of leishmaniasis. The current development of generic versions of LAMB and related challenges are also discussed. Expert opinion: LAMB proved to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level. Despite requiring higher doses, LAMB is the drug of choice to treat vulnerable groups (e...